{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:56:39Z","timestamp":1773496599953,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R014019\/1"],"award-info":[{"award-number":["MR\/R014019\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["294834\/Z\/16\/Z"],"award-info":[{"award-number":["294834\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this study is to explore the potential benefits of the IL-1\u03b2 antibody, canakinumab, in the treatment of AH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multicentre, double-blind, randomised placebo-controlled trial. Participants will be diagnosed with AH using clinical criteria. Liver biopsy will then confirm that all histological features of AH are present. Up to 58 participants will be recruited into two groups from 15 centres in the UK. Patients will receive an infusion of Canakinumab or matched placebo by random 1:1 allocation. The primary outcome is the difference between groups in the proportion of patients demonstrating histological improvement and will compare histological appearances at baseline with appearances at 28\u2009days to assign a category of \u201cimproved\u201d or \u201cnot improved\u201d. Patients with evidence of ongoing disease activity will receive a second infusion of canakinumab or placebo. Participants will be followed up for 90\u2009days. Secondary outcomes include mortality and change in MELD score at 90\u2009days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This phase II study will explore the benefits of the IL-1\u03b2 antibody, canakinumab, in the treatment of AH to provide proof of concept that inhibition of IL-1\u03b2 signalling may improve histology and survival for patients with AH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-003724-79\">2017-003724-79<\/jats:ext-link>. Prospectively registered on 13 April 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05719-2","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:03:39Z","timestamp":1636632219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-6757","authenticated-orcid":false,"given":"N.","family":"Vergis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bogdanowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Czyzewska-Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Thursz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"issue":"1","key":"5719_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014.","journal-title":"J Hepatol"},{"issue":"26","key":"5719_CR2","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1056\/NEJMra0805786","volume":"360","author":"MR Lucey","year":"2009","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758\u201369. https:\/\/doi.org\/10.1056\/NEJMra0805786.","journal-title":"N Engl J Med"},{"issue":"3","key":"5719_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1056\/NEJMc1506342","volume":"373","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Forrest EH, Ryder S. investigators S. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. N Engl J Med. 2015;373(3):282\u20133. https:\/\/doi.org\/10.1056\/NEJMc1506342.","journal-title":"N Engl J Med"},{"issue":"8","key":"5719_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.26442\/00403660.2019.08.000354","volume":"91","author":"CS Pavlov","year":"2019","unstructured":"Pavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis (Cochrane review). Ter Arkh. 2019;91(8):52\u201366. https:\/\/doi.org\/10.26442\/00403660.2019.08.000354.","journal-title":"Ter Arkh"},{"key":"5719_CR5","first-page":"CD001511","volume":"11","author":"CS Pavlov","year":"2017","unstructured":"Pavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev. 2017;11:CD001511.","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"5719_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","volume":"372","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1412278.","journal-title":"N Engl J Med"},{"issue":"2","key":"5719_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","volume":"155","author":"A Louvet","year":"2018","unstructured":"Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids Reduce Risk of Death Within 28\u2009Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology. 2018;155(2):458\u201368 e8. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.011.","journal-title":"Gastroenterology"},{"issue":"4","key":"5719_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","volume":"149","author":"S Singh","year":"2015","unstructured":"Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. Gastroenterology. 2015;149(4):958\u201370 e12. https:\/\/doi.org\/10.1053\/j.gastro.2015.06.006.","journal-title":"Gastroenterology"},{"issue":"2","key":"5719_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2012.04.004","volume":"57","author":"European Association for the Study of L","year":"2012","unstructured":"European Association for the Study of L. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399\u2013420. https:\/\/doi.org\/10.1016\/j.jhep.2012.04.004.","journal-title":"J Hepatol"},{"issue":"5","key":"5719_CR10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","volume":"152","author":"N Vergis","year":"2017","unstructured":"Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, et al. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. Gastroenterology. 2017;152(5):1068\u201377 e4. https:\/\/doi.org\/10.1053\/j.gastro.2016.12.019.","journal-title":"Gastroenterology"},{"issue":"5","key":"5719_CR11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/hep.20206","volume":"39","author":"S Naveau","year":"2004","unstructured":"Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390\u20137. https:\/\/doi.org\/10.1002\/hep.20206.","journal-title":"Hepatology"},{"issue":"3","key":"5719_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jhep.2017.11.017","volume":"68","author":"EH Forrest","year":"2018","unstructured":"Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, Thursz MR, et al. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. J Hepatol. 2018;68(3):511\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.017.","journal-title":"J Hepatol"},{"issue":"1","key":"5719_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/0016-5085(92)91122-K","volume":"103","author":"H Tilg","year":"1992","unstructured":"Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103(1):264\u201374. https:\/\/doi.org\/10.1016\/0016-5085(92)91122-K.","journal-title":"Gastroenterology"},{"issue":"3","key":"5719_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.28456","volume":"64","author":"H Tilg","year":"2016","unstructured":"Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology. 2016;64(3):955\u201365. https:\/\/doi.org\/10.1002\/hep.28456 Epub 2016 Mar 9.","journal-title":"Hepatology."},{"issue":"10","key":"5719_CR15","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1172\/JCI60777","volume":"122","author":"J Petrasek","year":"2012","unstructured":"Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122(10):3476\u201389. https:\/\/doi.org\/10.1172\/JCI60777 Epub 2012 Sep 4.","journal-title":"J Clin Invest"},{"issue":"5","key":"5719_CR16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/hep.26336","volume":"57","author":"S Mathews","year":"2013","unstructured":"Mathews S, Gao B. Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology. 2013;57(5):2078\u201380. https:\/\/doi.org\/10.1002\/hep.26336.","journal-title":"Hepatology"},{"issue":"6","key":"5719_CR17","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","volume":"135","author":"NC Boetticher","year":"2008","unstructured":"Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2008.08.057 Epub Sep 13.","journal-title":"Gastroenterology"},{"issue":"6","key":"5719_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","volume":"135","author":"NC Boetticher","year":"2008","unstructured":"Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2008.08.057.","journal-title":"Gastroenterology"},{"issue":"5","key":"5719_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/hep.20206","volume":"39","author":"S Naveau","year":"2004","unstructured":"Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390\u20137. https:\/\/doi.org\/10.1002\/hep.20206.","journal-title":"Hepatology"},{"issue":"5","key":"5719_CR20","doi-asserted-by":"publisher","first-page":"1231-9.e1-6","DOI":"10.1053\/j.gastro.2014.01.018","volume":"146","author":"J Altamirano","year":"2014","unstructured":"Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146(5):1231-9.e1-6. https:\/\/doi.org\/10.1053\/j.gastro.2014.01.018 Epub Jan 15.","journal-title":"Gastroenterology"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05719-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05719-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05719-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:08:42Z","timestamp":1636632522000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05719-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5719"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05719-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by London \u2013 Harrow Research Ethics Committee (REC reference 18\/LO\/0745) on 10 July 2018. Written informed consent will be obtained for all participants or the professional or personal representative.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The authors are willing to provide a model consent form on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"792"}}